Basilea Pharmaceutica Ltd logo

Basilea Pharmaceutica Ltd

LTS:0QNA (Switzerland)  
CHF 44.50 (+1.63%) May 15
Market Cap:
CHF 534.14M ($ 591.69M)
Enterprise V:
CHF 602.85M ($ 667.80M)
Volume:
2.53K
Avg Vol (2M):
4.64K
Also Trade In:
Volume:
2.53K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Basilea Pharmaceutica Ltd ( ) from 2014 to May 15 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Basilea Pharmaceutica stock (LTS:0QNA) PE ratio as of May 15 2024 is 68.17. More Details

Basilea Pharmaceutica Ltd (LTS:0QNA) PE Ratio (TTM) Chart

To

Basilea Pharmaceutica Ltd (LTS:0QNA) PE Ratio (TTM) Historical Data

Total 1275
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 15
Basilea Pharmaceutica PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-05-16 70.6 2024-03-14 57.5
2024-05-15 70.6 2024-03-13 57.0
2024-05-14 69.4 2024-03-12 60.5
2024-05-13 68.3 2024-03-11 60.5
2024-05-10 68.2 2024-03-08 60.4
2024-05-09 67.9 2024-03-07 59.8
2024-05-08 64.1 2024-03-06 58.9
2024-05-07 64.1 2024-03-05 58.3
2024-05-06 64.1 2024-03-04 56.1
2024-05-03 64.1 2024-03-01 55.8
2024-05-02 63.0 2024-02-29 56.4
2024-05-01 62.7 2024-02-28 57.1
2024-04-30 62.7 2024-02-27 57.1
2024-04-29 63.6 2024-02-26 57.6
2024-04-26 64.4 2024-02-23 57.6
2024-04-25 63.9 2024-02-22 58.7
2024-04-24 64.4 2024-02-21 57.6
2024-04-23 65.5 2024-02-20 59.0
2024-04-22 65.5 2024-02-19 59.3
2024-04-19 64.7 2024-02-16 59.4
2024-04-18 66.6 2024-02-15 59.9
2024-04-17 66.2 2024-02-14 59.0
2024-04-16 65.2 2024-02-13 57.9
2024-04-15 65.4 2024-02-12 52.4
2024-04-12 65.1 2024-02-09 51.3
2024-04-11 64.4 2024-02-08 51.2
2024-04-10 65.3 2024-02-07 51.6
2024-04-09 65.2 2024-02-06 52.8
2024-04-08 65.5 2024-02-05 51.8
2024-04-05 67.7 2024-02-02 52.3
2024-04-04 68.5 2024-02-01 52.5
2024-04-03 59.4 2024-01-31 53.7
2024-04-02 59.4 2024-01-30 54.0
2024-04-01 59.8 2024-01-29 53.9
2024-03-29 59.8 2024-01-26 54.7
2024-03-28 59.8 2024-01-25 53.7
2024-03-27 59.9 2024-01-24 55.5
2024-03-26 59.8 2024-01-23 53.6
2024-03-25 59.0 2024-01-22 53.9
2024-03-22 56.8 2024-01-19 53.9
2024-03-21 56.0 2024-01-18 51.4
2024-03-20 55.4 2024-01-17 52.1
2024-03-19 55.5 2024-01-16 54.3
2024-03-18 56.6 2024-01-15 55.0
2024-03-15 56.5 2024-01-12 56.4

Basilea Pharmaceutica Ltd (LTS:0QNA) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.